vs
Kiniksa Pharmaceuticals International, plc（KNSA）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Kiniksa Pharmaceuticals International, plc的季度营收约是STURM RUGER & CO INC的1.3倍（$202.1M vs $151.1M），Kiniksa Pharmaceuticals International, plc同比增速更快（65.0% vs 3.6%），Kiniksa Pharmaceuticals International, plc自由现金流更多（$53.3M vs $12.3M），过去两年Kiniksa Pharmaceuticals International, plc的营收复合增速更高（59.1% vs 5.1%）
Kiniksa Pharmaceuticals International plc是一家全球性生物制药企业，专注于发现、开发和商业化针对自身免疫性疾病、炎症性疾病及罕见病的靶向治疗药物，服务北美、欧洲、亚洲等主要市场的未被满足的临床需求。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
KNSA vs RGR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $202.1M | $151.1M |
| 净利润 | $14.2M | — |
| 毛利率 | 89.6% | 17.8% |
| 营业利润率 | 9.8% | 2.3% |
| 净利率 | 7.0% | — |
| 营收同比 | 65.0% | 3.6% |
| 净利润同比 | 259.8% | — |
| 每股收益（稀释后） | $0.18 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $202.1M | $151.1M | ||
| Q3 25 | $180.9M | $126.8M | ||
| Q2 25 | $156.8M | $132.5M | ||
| Q1 25 | $137.8M | $135.7M | ||
| Q4 24 | $122.5M | $145.8M | ||
| Q3 24 | $112.2M | $122.3M | ||
| Q2 24 | $108.6M | $130.8M | ||
| Q1 24 | $79.9M | $136.8M |
| Q4 25 | $14.2M | — | ||
| Q3 25 | $18.4M | $1.6M | ||
| Q2 25 | $17.8M | $-17.2M | ||
| Q1 25 | $8.5M | $7.8M | ||
| Q4 24 | $-8.9M | — | ||
| Q3 24 | $-12.7M | $4.7M | ||
| Q2 24 | $-3.9M | $8.3M | ||
| Q1 24 | $-17.7M | $7.1M |
| Q4 25 | 89.6% | 17.8% | ||
| Q3 25 | 88.8% | 15.1% | ||
| Q2 25 | 88.1% | 3.9% | ||
| Q1 25 | 87.0% | 22.0% | ||
| Q4 24 | 85.4% | 22.8% | ||
| Q3 24 | 82.1% | 18.5% | ||
| Q2 24 | 88.7% | 22.3% | ||
| Q1 24 | 86.7% | 21.5% |
| Q4 25 | 9.8% | 2.3% | ||
| Q3 25 | 13.3% | -2.7% | ||
| Q2 25 | 12.9% | -15.6% | ||
| Q1 25 | 9.6% | 6.2% | ||
| Q4 24 | -15.7% | 7.8% | ||
| Q3 24 | -8.6% | 3.1% | ||
| Q2 24 | -0.1% | 6.9% | ||
| Q1 24 | -20.7% | 5.5% |
| Q4 25 | 7.0% | — | ||
| Q3 25 | 10.2% | 1.2% | ||
| Q2 25 | 11.4% | -13.0% | ||
| Q1 25 | 6.2% | 5.7% | ||
| Q4 24 | -7.3% | — | ||
| Q3 24 | -11.3% | 3.9% | ||
| Q2 24 | -3.6% | 6.3% | ||
| Q1 24 | -22.2% | 5.2% |
| Q4 25 | $0.18 | $0.22 | ||
| Q3 25 | $0.23 | $0.10 | ||
| Q2 25 | $0.23 | $-1.05 | ||
| Q1 25 | $0.11 | $0.46 | ||
| Q4 24 | $-0.11 | $0.62 | ||
| Q3 24 | $-0.18 | $0.28 | ||
| Q2 24 | $-0.06 | $0.47 | ||
| Q1 24 | $-0.25 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $414.1M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $567.6M | $283.8M |
| 总资产 | $763.6M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $414.1M | $92.5M | ||
| Q3 25 | $352.1M | $80.8M | ||
| Q2 25 | $307.8M | $101.4M | ||
| Q1 25 | $268.3M | $108.3M | ||
| Q4 24 | $243.6M | $105.5M | ||
| Q3 24 | $223.8M | $96.0M | ||
| Q2 24 | $218.8M | $105.6M | ||
| Q1 24 | $213.6M | $115.3M |
| Q4 25 | $567.6M | $283.8M | ||
| Q3 25 | $535.4M | $279.6M | ||
| Q2 25 | $495.0M | $289.3M | ||
| Q1 25 | $457.5M | $321.5M | ||
| Q4 24 | $438.4M | $319.6M | ||
| Q3 24 | $437.0M | $314.9M | ||
| Q2 24 | $435.1M | $321.5M | ||
| Q1 24 | $431.9M | $332.0M |
| Q4 25 | $763.6M | $342.0M | ||
| Q3 25 | $712.3M | $342.3M | ||
| Q2 25 | $661.1M | $349.5M | ||
| Q1 25 | $599.3M | $379.0M | ||
| Q4 24 | $580.6M | $384.0M | ||
| Q3 24 | $555.3M | $373.5M | ||
| Q2 24 | $542.4M | $376.7M | ||
| Q1 24 | $519.7M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.9M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $53.3M | $12.3M |
| 自由现金流率自由现金流/营收 | 26.4% | 8.2% |
| 资本支出强度资本支出/营收 | 0.3% | 2.1% |
| 现金转化率经营现金流/净利润 | 3.80× | — |
| 过去12个月自由现金流最近4个季度 | $136.4M | $38.5M |
8季度趋势，按日历期对齐
| Q4 25 | $53.9M | $15.5M | ||
| Q3 25 | $33.7M | $12.9M | ||
| Q2 25 | $28.1M | $14.7M | ||
| Q1 25 | $22.3M | $11.1M | ||
| Q4 24 | $18.8M | $20.0M | ||
| Q3 24 | $-2.2M | $9.4M | ||
| Q2 24 | $5.2M | $18.7M | ||
| Q1 24 | $4.0M | $7.3M |
| Q4 25 | $53.3M | $12.3M | ||
| Q3 25 | $33.0M | $7.0M | ||
| Q2 25 | $27.9M | $9.1M | ||
| Q1 25 | $22.2M | $10.0M | ||
| Q4 24 | $18.6M | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | $3.9M | $5.6M |
| Q4 25 | 26.4% | 8.2% | ||
| Q3 25 | 18.2% | 5.5% | ||
| Q2 25 | 17.8% | 6.9% | ||
| Q1 25 | 16.1% | 7.4% | ||
| Q4 24 | 15.2% | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | 4.9% | 4.1% |
| Q4 25 | 0.3% | 2.1% | ||
| Q3 25 | 0.4% | 4.6% | ||
| Q2 25 | 0.1% | 4.2% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.2% | 2.5% | ||
| Q3 24 | 0.0% | 5.5% | ||
| Q2 24 | 0.0% | 6.6% | ||
| Q1 24 | 0.1% | 1.3% |
| Q4 25 | 3.80× | — | ||
| Q3 25 | 1.83× | 8.15× | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 2.61× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KNSA
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
